Loading data for DARE — first visit, this takes a few seconds.
Daré Bioscience Inc. (DARE)
NasdaqCM: DARE
· Real-Time Price · USD
0.82
+0.02 (2.50%)
At close: Aug 27, 2026, 3:59 PM
The price, the headline numbers and the latest news, in one place.
Daré Bioscience Inc. (DARE) Stock Price, Analysis & Data
2.50% (1D)
| Bid | 0.59 |
| Market Cap | 14.31M |
| Revenue (ttm) | 1.37M |
| Net Income (ttm) | -10.99M |
| 1.05 | |
| -0.66 | |
| n/a | |
| -1.78 | |
| P/B (ttm) | -19.96 |
| P/S (ttm) | 10.48 |
| Earnings Date | Nov 12, 2026 |
| Ask | 1.05 |
| Volume | 616,012 |
| Avg. Volume (20D) | 465,750 |
| Open | 0.82 |
| Previous Close | 0.80 |
| Day's Range | 0.80 - 0.85 |
| 52-Week Range | 0.75 - 3.78 |
| Analyst | n/a |
| Price Target | n/a |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About DARE
Daré Bioscience, Inc. develops therapies in the areas of contraception, pelvic pain, fertility, infectious disease, menopause, and sexual and vaginal health in the United States. The company offers XACIATO, a lincosamide antibacterial gel for the treatment of bacterial vaginosis. It also develops Ovaprene, a hormone-free monthly intravaginal contraceptive; Sildenafil Cream, a cream formulation of sildenafil for topical administration to the femal...
Industry Biotechnology
Sector Healthcare
IPO Date Apr 10, 2014
Employees 21
Stock Exchange NasdaqCM
Ticker Symbol DARE
Website https://darebioscience.com
Financial Performance
In 2025, Daré Bioscience's revenue was 1.03M, an increase of 10,429.36% compared to the previous year's 9.78K. Earnings were -13.4M, an increase of 230.55%.
Financial StatementsEarnings Surprise
Daré Bioscience has released their quarterly earnings on Aug 13, 2026:
- Revenue of $152.46K misses estimates by $0, with 499.58% YoY growth.
- EPS of -0.2 exceeds estimates by 0.10, with 55.56% YoY growth.
Daré Bioscience Inc. is scheduled to release its earnings on Nov 12, 2026, during market hours.
Analysts project revenue of ... Upgrade
Analysts project revenue of ... Upgrade
Page 1 of 2